Sionna Therapeutics, Inc.
Sionna Therapeutics develops small-molecule CFTR modulators targeting nucleotide binding domain 1 to restore CFTR protein function in cystic fibrosis.
SCHEDULE 13D/ASep 21Latest SEC filing
Sep 14Latest story
Sign inSign inSionna Therapeutics develops small-molecule CFTR modulators targeting nucleotide binding domain 1 to restore CFTR protein function in cystic fibrosis.